Skip to content
  • Home
  • About Us
  • Shop
    • Chinese innovative drug
    • Tablets
    • Capsules
    • Injection
    • oral solution
    • Cream/Gel/Ointment
    • ophthalmic preparations
    • Nasal preparations
    • Inhalation preparation
    • Implant
    • Chinese Medicine
  • Blog
  • Contact Us
Xpharma China
Shopping cart$0.00 0
Login
  • Home
  • About Us
  • Shop
    • Chinese innovative drug
    • Tablets
    • Capsules
    • Injection
    • oral solution
    • Cream/Gel/Ointment
    • ophthalmic preparations
    • Nasal preparations
    • Inhalation preparation
    • Implant
    • Chinese Medicine
  • Blog
  • Contact Us
Xpharma China
CRESEMBA (Isavuconazonium Sulfate Capsules)
  • Drug news

How much does CRESEMBA (Isavuconazonium Sulfate Capsules) Cost& price without insurance in China?

NEFECON (Budesonide Enteric Capsules)
  • Drug news

How much does NEFECON (Budesonide Enteric Capsules) Cost& price without insurance in China?

MaiFantuo (Mavacamten Capsules)
  • Drug news

How much does MaiFantuo (Mavacamten Capsules) Cost& price without insurance in China?

Evrenzo (Roxadustat Capsules)
  • Drug news

How much does Evrenzo (Roxadustat Capsules) Cost& price without insurance in China?

  • Drug development

Hangzhou Hertz Pharmaceutical Co. Ltd.’s Pan-RAS molecular glue HZ-V055 clinical trial application has been accepted

  • Approved News

The first domestic HER2 bispecific antibody, Anbenitamab injection (KN026), has been approved for marketing, from Alphamab Oncology / CSPC Pharmaceutical Group

  • Approved News

Hengrui Pharma’s new gout drug SHR4640 has been approved for marketing

  • Approved News

Beijing Northland Biotechnology’s gene therapy drug NL003 gets approval for market

Linzess (Linaclotide Capsules)
  • Drug news

How much does Linzess (Linaclotide Capsules) Cost& price without insurance in China?

  • Drug development

Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome

  • Approved News

Johnson & Johnson: IMAAVY® Nipocalimab Injection approved for market by NMPA

  • Approved News

Yangtze River Pharmaceutical Group (YRPG): Fazamorexant Tablets Class 1 new anti-insomnia drug approved for market

Prev
1 … 18 19 20 21 22
Next
Contact us

WeChat: +86 139 2425 9988
WhatsApp : +852 9100 6363
Email: info@xpharma.com.cn

Rm F2-48, 6/F, No. 47 Guomao Road, Hainan, China

Useful Links
  • Medicines
  • Chinese innovative drug
  • Medicines Approved News
  • Drug Development News
  • Drug News
  • Privacy Policy
Email Newsletter

Subscribe to our newsletter and get 10% off your first purchase

Copyright © {2026} -Xpharma China